Revenue Update on Spectrum Pharmaceuticals(NASDAQ:SPPI)

Spectrum Pharmaceuticals(NASDAQ:SPPI) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 9, 2016. Company reported revenue of $33.95M. Analysts estimated a revenue of $30.88M. Earnings per share were $-0.05. Analysts had estimated an EPS of $-0.29.

Spectrum Pharmaceuticals (SPPI) shares turned negative on Wednesdays trading session with the shares closing down -0.02 points or -0.34% at a volume of 9,81,261. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $6.035. The peak price level was also seen at $6.035 while the days lowest was $5.82. Finally the shares closed at $5.91. The 52-week high of the shares is $7.74 while the 52-week low is $4.14. According to the latest information available, the market cap of the company is $474 M.

Spectrum Pharmaceuticals Inc. is a biotechnology Company. The Company is engaged in commercial and drug development operations with a focus on hematology and oncology. The Company is engaged in acquiring developing and commercializing the pipeline of late-stage clinical and commercial drug compounds. The Company market five drugs for the treatment of cancer which includes FUSILEV injection for patients with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy; ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; FOLOTYN injection for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); MARQIBO injection for patients with Philadelphia chromosome–negative acute lymphoblastic leukemia and BELEODAQ injection for patients with relapsed or refractory PTCL.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *